Comprehensive genomic profiling for cancer
3 Jul 2024
Decoding the differences of cancer at a genomic level is key to precision oncology. Agilent's SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay and workflow detects biomarkers from solid tumors by profiling clinically relevant genes and assessing key classes of mutations to gain insights into tumors. The assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries.
Related Products
Request Quote for All Products
SureSelect Cancer CGP Assay
Agilent TechnologiesSureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability).
SureSelect Cancer Custom Panels
Agilent TechnologiesRapidly design your NGS panels for tumor genomic profiling to fit your specific requirements, including incorporation of new and emerging biomarkers. Leverage the curated content of the SureSelect Cancer CGP and Tumor-Specific catalog DNA panels to add or subtract gene content in the SureDesign web portal.
SureSelect Cancer Tumor-Specific Assays
Agilent TechnologiesSureSelect Cancer Tumor-Specific assays offer genomic profiling for solid tumors from lung, colon, pancreas, kidney, or bladder tissue, to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), and translocations (TLs). These small cancer panels enable affordable tumor genomic profiling.
